ILLUMINATE-A 3期试验最终结果:Lumasiran治疗原发性高草酸尿症1型
ILLUMINATE-A是一项为期60个月的3期跨国临床试验,纳入39例≥6岁、经基因确诊的PH1患者,先进行6个月双盲安慰剂对照期,随后所有患者接受lumasiran治疗至54个月。结果显示24小时尿草酸和血浆草酸持续降低,eGFR保持稳定,肾结石事件率低,髓质肾钙沉着症改善,安全性可接受。
要点
- Lumasiran治疗60个月持续降低尿草酸和血浆草酸。
- eGFR保持稳定,肾结石事件率低,肾钙沉着症改善。
- 安全性可接受,注射部位反应为最常见不良事件。
核心结论
- Lumasiran治疗长达60个月与尿草酸排泄和血浆草酸浓度持续降低相关,临床结局良好。
研究设计与样本
- ILLUMINATE-A为60个月3期跨国临床试验,包括6个月双盲安慰剂对照期和最长54个月治疗延长期。
- 纳入39例≥6岁、基因确诊PH1、eGFR≥30 ml/min/1.73 m²且24小时尿草酸≥0.70 mmol/24h/1.73 m²的患者。
主要发现
- 第60个月时,lumasiran/lumasiran组和安慰剂/lumasiran组24小时尿草酸平均降幅分别为54%(SEM 6%)和54%(SEM 8%)。
- 第60个月时,两组血浆草酸浓度平均分别下降35%(SEM 5%)和38%(SEM 7%)。
- 两组eGFR研究期间保持稳定,肾结石事件率分别为0.47(95%CI 0.36-0.62)和0.54(95%CI 0.37-0.78)每患者年。
- 基线有肾钙沉着症且完成研究评估的28例中,21例(75%)研究结束时分级改善。
- 安全性可接受,注射部位反应最常见,多数不良事件为轻中度。
临床怎么用
- 对于符合条件的PH1患者,lumasiran可长期使用以持续降低草酸负荷并稳定肾功能。
- 治疗期间应监测注射部位反应,多数不良事件为轻中度。
局限性
- 样本量较小(39例),延长期无安慰剂对照。
- 研究纳入eGFR≥30 ml/min/1.73 m²的患者,结果不能外推至更严重肾功能不全者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Primary hyperoxaluria type 1 is a genetic disorder associated with hepatic oxalate overproduction, kidney failure, and systemic oxalosis. Lumasiran treatment for up to 60 months was associated with sustained reductions in urinary and plasma oxalate and encouraging clinical outcomes. Lumasiran's safety profile was acceptable with mild injection site reactions being the most common adverse events. BACKGROUND: Primary hyperoxaluria type 1 (PH1) is characterized by hepatic oxalate overproduction, kidney stones, and progressive kidney disease. Lumasiran is the first approved treatment for PH1. METHODS: ILLUMINATE-A ( NCT03681184 ) was a 60-month pivotal, phase 3, multinational clinical trial of lumasiran which consisted of a 6-month double-blind, placebo-controlled period (6M DB), followed by a treatment extension period of up to 54 months in which all patients received lumasiran. Eligible patients were aged ≥6 years with genetically confirmed PH1, eGFR ≥30 ml/min per 1.73 m 2 , and mean 24-hour urinary oxalate (UOx) excretion ≥0.70 mmol/24 h per 1.73 m 2 . RESULTS: Of 39 patients enrolled, 24 of 26 randomized to lumasiran in the 6M DB (lumasiran/lumasiran group) and 13 of 13 randomized to placebo in the 6M DB (placebo/lumasiran group) completed the study. Sustained reductions in 24-hour UOx were observed in both treatment groups. At month 60 relative to study baseline, the mean (SEM) 24-hour UOx percentage reductions were 54 (6) and 54% (8%) in the lumasiran/lumasiran and placebo/lumasiran groups, respectively, and the mean (SEM) plasma oxalate concentrations had decreased by 35 (5) and 38% (7%). eGFR remained stable through the end of the study in both treatment groups. Kidney stone event rates during the study were 0.47 (95% confidence interval, 0.36 to 0.62) and 0.54 (0.37 to 0.78) per patient-year in the lumasiran/lumasiran group and placebo/lumasiran group, respectively. Medullary nephrocalcinosis grade improved at the end of the study in 21 of 28 (75%) patients with nephrocalcinosis at baseline and an end of study assessment. The safety profile of lumasiran was acceptable. Injection site reactions were the most common adverse events during lumasiran treatment. Most adverse events were mild or moderate in severity. CONCLUSIONS: Lumasiran treatment for up to 60 months in ILLUMINATE-A was associated with sustained reductions in UOx excretion and plasma oxalate concentration, encouraging clinical outcomes including stable eGFR in a population that would be expected to show eGFR decline, reduced kidney stone event rates, improved medullary nephrocalcinosis, and indications of improved health-related quality of life.Clinical Trial registry name and registration number: ClinicalTrials.gov NCT03681184 .
引用
- Frishberg Y, Saland JM, Lieske JC, et al. Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1. Clin J Am Soc Nephrol. 2025. PMID: 41343248. doi:10.2215/CJN.0000000916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。